ProCE Banner Activity

An Interactive Tool for Managing AEs With Oral Targeted Therapies for HR+, HER2– Breast Cancer

Tool

Use this Interactive Decision Support Tool to learn strategies to assess and manage adverse events associated with oral targeted therapy for HR-positive, HER2-negative breast cancer from 5 experts.

Released: September 14, 2021

Expiration: September 13, 2022

Share

Supporters

Supported by an educational grant from

Lilly

Partners

Smart Patients

ProCE Banner

Additional Information

Program Medium

This program has been made available online.